The neuropeptide genes SST , TAC1 , HCRT , NPY , and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis

Staging and pathological grading systems are convenient but imperfect predictors of recurrence in head and neck squamous cell carcinoma (HNSCC). Identifying biomarkers for HNSCC that will progress and cause death is a critical research area, particularly if the biomarker can be linked to selection of patients. Therefore, to identify potential alternative prognostic markers, we investigated the methylation status of five neuropeptide gene promoters. The promoter methylation status was determined by quantitative methylation-specific PCR in 230 cases of HNSCC; 58 hypopharynx, 45 larynx, 56 oropharynx, and 71 oral cavity tumor samples were studied. The somatostatin ( ), tachykinin precursor 1 ( ), hypocretin neuropeptide precursor ( ), neuropeptide Y ( ), and galanin ( ) promoters were methylated in 84.3, 63.5, 32.6, 28.3, and 20.0%, respectively, of the samples. The mean number of methylated genes per sample was 2.29 (range, 0-5). Disease-free survival was lower in patients with 3-5 methylated genes than in those with 0-2 methylated genes (log-rank test, = 0.007). In multivariate Cox proportional hazards analysis, and promoter methylation independently predicted recurrence (odds ratios 1.620, 95% confidence interval [CI] 1.018-2.578, = 0.042, and odds ratios 1.692, 95% CI 1.063-2.694, = 0.027, respectively). In patients with oral cancer, methylation showed the best correlation with poor survival (odds ratio 4.427, 95% CI 1.634-12.00, = 0.003). Similar findings were observed for and in patients with laryngeal cancer and oropharyngeal cancer, respectively. In this study, we demonstrated the methylation status of the neuropeptide-encoding genes , , , , and and its relationship with recurrence and survival in HNSCC. These methylation changes may serve as potential molecular markers for defining the risk and prognosis of HNSCC.